Status:
COMPLETED
Pazopanib Maintenance for SCLC
Lead Sponsor:
Samsung Medical Center
Conditions:
SCLC
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.
Eligibility Criteria
Inclusion
- histologically confirmed SCLC
- no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
- history of 4 cycles of etoposide/platinum 1st-line therapy
- between 21 days and 42 days since C4D1 of etoposide/platinum
- no symptomatic brain meta
Exclusion
- poor hepatic, renal function
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT01797874
Start Date
June 1 2013
End Date
December 1 2017
Last Update
December 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710